Louis Grasmick Net Worth

The estimated Net Worth of Louis J Grasmick is at least $4.43 Million dollars as of 16 March 2016. Mr. Grasmick owns over 91,369 units of Capricor Therapeutics Inc stock worth over $4,429,713 and over the last 10 years he sold CAPR stock worth over $0. In addition, he makes $0 as Independent Director at Capricor Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Grasmick CAPR stock SEC Form 4 insiders trading

Louis has made over 4 trades of the Capricor Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 91,369 units of CAPR stock worth $219,286 on 16 March 2016.

The largest trade he's ever made was buying 141,924 units of Capricor Therapeutics Inc stock on 21 January 2015 worth over $499,572. On average, Louis trades about 67,312 units every 84 days since 2015. As of 16 March 2016 he still owns at least 1,059,740 units of Capricor Therapeutics Inc stock.

You can see the complete history of Mr. Grasmick stock trades at the bottom of the page.

Louis Grasmick biography

Louis J. Grasmick is Independent Director of CAPRICOR THERAPEUTICS. He was one of the initial investors in Capricor and joined the Capricor Board of Directors in 2006. Mr. Grasmick is a prominent Baltimore philanthropist and entrepreneur with over fifty years of executive experience. He is the chief executive officer of the Louis J. Grasmick Lumber Company, a supplier of industrial lumber, which he founded after playing professional baseball for seven years. His many accomplishments and positions include being director of the Harbor Bank of Maryland’s Executive Committee, as well as past president of Signal 13, a non-profit organization. Mr. Grasmick currently sits on the board of directors for The Johns Hopkins Hospital Broccoli Center. Voted “Man of the Year” by both the Baltimore Junior Association of Commerce and the Variety Club, He was also honored by the Children’s Guild of Maryland in 2009 with their award for “Making the Impossible Possible.”

How old is Louis Grasmick?

Louis Grasmick is 90, he's been the Independent Director of Capricor Therapeutics Inc since 2013. There are no older and 17 younger executives at Capricor Therapeutics Inc.

What's Louis Grasmick's mailing address?

Louis's mailing address filed with the SEC is C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS, CA, 90211.

Insiders trading at Capricor Therapeutics Inc

Over the last 11 years, insiders at Capricor Therapeutics Inc have traded over $949,404,468 worth of Capricor Therapeutics Inc stock and bought 6,444,826 units worth $18,843,106 . The most active insiders traders include Sinai Medical Center Cedars, John Edward A.Edward St. Jo... und Gregory W Schafer. On average, Capricor Therapeutics Inc executives and independent directors trade stock every 58 days with the average trade being worth of $494,068. The most recent stock trade was executed by David B Musket on 7 August 2024, trading 34,000 units of CAPR stock currently worth $47,260.

What does Capricor Therapeutics Inc do?

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has

Complete history of Mr. Grasmick stock trades at Capricor Therapeutics Inc

Capricor Therapeutics Inc executives and stock owners

Capricor Therapeutics Inc executives and other stock owners filed with the SEC include:

• Karen G. Krasney,
  Exec. VP, Gen. Counsel & Sec.
• Anthony J. Bergmann M.B.A.,
  CFO & Corp. Treasurer
• Karen Krasney,
  Executive Vice President, General Counsel
• Linda Marban,
  President, Chief Executive Officer, Director
• Dr. Linda Marbán,
  Co-Founder, Pres, CEO & Director
• Dr. Frank Isaac Litvack FACC, M.D.,
  Exec. Chairman
• Dr. Frank Isaac Litvack M.D., FACC,
  Exec. Chairman
• Joshua Kazam,
  Director
• David Musket,
  Independent Director
• Louis Manzo,
  Independent Director
• Louis Grasmick,
  Independent Director
• George Dunbar,
  Independent Director
• Earl Collier,
  Independent Director
• Deborah Ascheim,
  Chief Medical Officer
• Rachel Smith,
  Vice President - Research & Development
• Luis Rodriguez-Borlado,
  Vice President - Regenerative Therapies
• Houman Hemmati,
  Vice President - Medical & Clinical Development, New Therapies
• Thomas Copmann,
  Vice President - Regulatory Affairs and Drug Development
• Anthony Bergmann,
  Chief Financial Officer, Principal Accounting Officer
• Frank Litvack,
  Independent Executive Chairman of the Board
• Catherine Lee Kelleher,
  Consultant
• Dr. Deborah D. Ascheim,
  Consultant
• Dr. Eduardo Marbán,
  Co-Founder & Chairman of Scientific Advisory Board
• Leland Gershell,
  CHIEF FINANCIAL OFFICER
• John Edward A.Edward St. Jo...,
  
• Sinai Medical Center Cedars,
  10% owner
• Xavier Avat,
  
• Philip J Gotwals,
  
• Paul Gisbert Auwaerter,
  
• Eduardo Marban,
  10% owner
• Gregory W Schafer,
  Director
• Mike Kelliher,
  
• Karimah Es Sabar,